Table 1 Patient cohort characteristics. GPA: granulomatosis with polyangiitis, MPA: microscopic polyangiitis, IIF: indirect immunofluorescence of anti-neutrophil cytoplasmic antibodies, RTX: rituximab, CYC: cyclophosphamide, BVAS: Birmingham vasculitis activity score, GC: glucocorticoids, AZA: azathioprine, MTX: methotrexate, MMF: mycophenolate mofetil, COTRIM: trimethoprim/sulfomethoxazol, CRP: C-reactive protein in peripheral blood, eGFR: estimated glomerular filtration rate (MDRD formula), s.d.: standard deviation. Disease duration was defined as the period from initial diagnosis until study inclusion.
Diagnosis | Age | Gender | IIF | RTX/CYC in history | BVAS | Immunosuppression/Medication at point of study enrolment | Disease duration [months] | Time in remission [months] | Relapse rate [relapse/month] | CRP [mg/l] | Creatinine [mg/dl]/eGFR [ml/min] | Samples used in experiments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GPA | 82 | F | cANCA | RTX,CYC | 0 | GC | 182.8 | 28.6 | 0.027 | 37.9 | 1.4/38 | miR |
MPA | 75 | F | pANCA | CYC | 0 | GC, AZA | 170.6 | 64.1 | 0.006 | <2.9 | 1.65/32 | FACS, miR |
GPA | 75 | M | cANCA | RTX, CYC | 0 | GC, COTRIM | 243.9 | 9.3 | 0.004 | 17.6 | 4.27/14 | FACS, miR |
GPA | 72 | M | cANCA | RTX, CYC | 29 | GC | 0.6 | 0 | 0 | 118 | 5.21/12 | FACS, miR |
GPA | 21 | M | cANCA | RTX, CYC | 0 | GC, COTRIM | 51.6 | 2.9 | 0.019 | <2.9 | 0.93/>60 | FACS, miR |
GPA | 74 | F | pANCA | RTX, CYC | 0 | GC | 83 | 19.1 | 0.012 | 9 | 1.21/46 | FACS, miR |
MPA | 78 | M | pANCA | CYC | 0 | GC, AZA, COTRIM | 40.4 | 40.4 | 0 | 7.5 | 0.89/>60 | miR |
GPA | 24 | F | cANCA | RTX | 0 | GC, COTRIM | 11.4 | 11.4 | 0 | <2.9 | 1.08/>60 | FACS, miR |
MPA | 59 | M | pANCA | — | 0 | GC, MTX | 28.7 | 28.7 | 0 | 5 | 1.24/>60 | FACS, miR |
GPA | 36 | F | negative | — | 0 | GC, MTX | 18 | 7.8 | 0.056 | 7.3 | 0.76/>60 | FACS, miR |
GPA | 33 | F | cANCA | RTX, CYC | 0 | GC | 45.3 | 3.8 | 0.022 | <2.9 | 1.29/50 | FACS, miR |
GPA | 18 | M | cANCA | RTX, CYC | 0 | GC, COTRIM | 5 | 5 | 0 | <2.9 | 0.87/>60 | FACS, miR |
GPA | 75 | F | cANCA | RTX, CYC | 0 | GC | 205.9 | 17.2 | 0.024 | 24.5 | 0.76/>60 | FACS, miR |
GPA | 55 | F | cANCA | — | 0 | GC | 165.6 | 92.5 | 0.012 | 41.3 | 2.82/19 | FACS, miR |
GPA | 28 | M | cANCA | RTX, CYC | 0 | GC, AZA | 114.8 | 28.6 | 0.078 | <2.9 | 0.91/>60 | FACS, miR |
MPA | 69 | M | cANCA | — | 0 | MMF | 206.1 | 156.4 | 0.005 | 31.8 | 4.36/14 | FACS, miR |
GPA | 75 | M | pANCA | CYC | 0 | GC, AZA, COTRIM | 45.2 | 45.2 | 0 | 9.4 | 1.51/48 | FACS |
GPA | 65 | F | pANCA | CYC | 6 | GC | 88.9 | 0 | 0.011 | 14.2 | 0.75/>60 | FACS, miR |
GPA | 82 | M | cANCA | CYC | 0 | GC, MTX | 187.8 | 187.8 | 0 | <2.9 | 1.37/53 | FACS, miR |
GPA | 80 | M | cANCA | — | 0 | GC, AZA | 70 | 70 | 0 | <2.9 | 1.81/39 | FACS, miR |
MPA | 67 | F | pANCA | RTX | 0 | GC, COTRIM | 18.4 | 18.4 | 0 | 18.7 | 2.45/21 | FACS, miR |
MPA | 82 | F | cANCA | RTX, CYC | 0 | GC, AZA | 41.9 | 41.9 | 0 | <2.9 | 1.28/42 | FACS, miR |
GPA | 57 | F | cANCA | — | 2 | GC, MTX | 59.4 | 0 | 0 | <2.9 | 0.96/>60 | FACS, miR |
MPA | 86 | F | cANCA | RTX, CYC | 0 | — | 32 | 32 | 0 | <2.9 | 1.38/39 | FACS, miR |
MPA | 77 | M | pANCA | — | 18 | GC | 0.6 | 0 | 0 | 93.1 | 4.26/14 | FACS, miR |
GPA | 62 | M | cANCA | CYC | 0 | GC, AZA | 61.6 | 61.6 | 0 | <2.9 | 2.34/30 | FACS, miR |
GPA | 52 | M | cANCA | — | 0 | GC, COTRIM | 14 | 7.9 | 0.071 | 15.2 | 1.65/47 | FACS, miR |
MPA | 75 | M | cANCA | CYC | 0 | GC, MMF | 202.7 | 19.1 | 0.005 | 10.1 | 2.13/32 | FACS, miR |
GPA | 61 | M | cANCA | RTX, CYC | 18 | GC, AZA, COTRIM | 132.9 | 0 | 0.015 | <2.9 | 3.64/18 | FACS, miR |
GPA | 53 | M | cANCA | RTX | 9 | GC | 0.3 | 0 | 0 | 3.6 | 0.87/>60 | FACS, miR |
MPA | 62 | M | pANCA | RTX, CYC | 0 | — | 159.7 | 127.3 | 0.006 | <2.9 | 1.91/38 | FACS, miR |
GPA: n = 21 MPA: n = 10 | Mean ± s.d.: 69 ± 19.8 years | M: n = 17 F: n = 14 | cANCA: n = 21 pANCA: n = 9 seronegative: n = 1 | RTX: n = 16 CYC: n = 20 | Mean ± s.d.: 86.8 ± 76.1 months | Mean ± s.d.: 36.4 ± 47.25 months | Mean ± s.d.: 0 ± 0.021 relapse/month | Mean ± s.d.: 27.3 ± 31.8 mg/l | Mean ± s.d.: Creatinine 1.87 ± 1.24 mg/dl eGFR 32.3 ± 13.7 ml/min |
